Support #Liver and #BileDuctCancer Research! We're participating in @Cycle4Survival to raise money for rare cancer research at @MSKCancerCenter, and your support would mean so much to us. Make a 100% tax-deductible donation using the link. Thank you! https://t.co/i2irFY24tT
This time of year is always the hardest! It has been my pleasure to work with this gang all year, who have been the most supportive colleagues one can dream of. The New York adventure begins! 🥰
🔥NeoPancOne🇨🇦
➡️mFFX in resectable PDAC
➡️exploring GATA6&subtypes
➡️mEFS &OS 16.3 &34.2mths
➡️1yr EFS 90% in GATA6 hi vs 50% lo
➡️1yr OS classical 95% vs.57% basal-like
⭐️Time to subtype upfront in all PDAC recognising plasticity @OncoAlert#ASCO25@OICR_news@pmcancercentre
@mccarthymt7@MSKCC_OncoNotes@ASCO Thank you for your super advice throughout this project! I agree - the public-private divide adds an extra layer of complexity and exclusion
Amazing to be at #ESMO2024 and see novel trials and development of drugs for onc patients across a wide range of malignancies, but we need patient access.
Here we highlight that patients in Ireland are accessing treatments more than x2 as slow as the UK. Let's push for change!
Congratulations to the 2024 Novartis Oncology Young Canadian Investigator Award recipients!
A Canadian contingent of more than 90 attended the #NOYCIAAwards at #ASCO2024 to see our 10 #NOYCIA recipients present their winning research, showcasing Canada’s significant contribution to #oncology.
Visit https://t.co/YQuTpzeQAp for more information.
Well done @RonanAndrewMcL1 and @graokane - amazing work looking at GATA6 expression as a predictive and prognostic biomarker in advanced PDAC. Congrats to all involved 👏 #ASCO2024
I'm not sure it's possible to be more excited!! Absolutely honoured to get the Tomás Lyons Advanced Oncology fellowship @MSKCancerCenter. Thanks to all for all the advice and mentorship along the way 😊🥰
Delighted to be back at #GI24 presenting our poster with @ARFhsereg and Dr Elena Elimova on the Princess Margaret Cancer Centre outcomes in de novo versus recurrent metastatic gastroesophageal cancer. Continuing a well established track of Irish oncology trainees thriving at PMCC
Honoured to deliver the Claude Smith lectureship @hopkinskimmel where many 🇮🇪oncologists are trained & find their homes! Excited to discuss progress in #PancreaticCancer & highlight how international collaborations are pushing the boundaries 🇨🇦🇺🇸🇮🇪